|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: KHDRBS2 |
Gene summary for KHDRBS2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | KHDRBS2 | Gene ID | 202559 |
| Gene name | KH RNA binding domain containing, signal transduction associated 2 | |
| Gene Alias | SLM-1 | |
| Cytomap | 6q11.1 | |
| Gene Type | protein-coding | GO ID | GO:0000375 | UniProtAcc | Q5VWX1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 202559 | KHDRBS2 | RNA-P23T2-P23T2-1 | Human | Lung | MIAC | 4.45e-03 | 1.03e+00 | -0.037 |
| 202559 | KHDRBS2 | RNA-P23T2-P23T2-2 | Human | Lung | MIAC | 1.87e-06 | 1.11e+00 | -0.028 |
| 202559 | KHDRBS2 | RNA-P23T2-P23T2-4 | Human | Lung | MIAC | 2.54e-08 | 1.46e+00 | -0.0272 |
| 202559 | KHDRBS2 | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 1.56e-05 | 4.44e-01 | -0.2116 |
| 202559 | KHDRBS2 | RNA-P25T1-P25T1-3 | Human | Lung | AIS | 4.07e-03 | 5.50e-01 | -0.2107 |
| 202559 | KHDRBS2 | RNA-P25T1-P25T1-4 | Human | Lung | AIS | 2.65e-07 | 6.15e-01 | -0.2119 |
| 202559 | KHDRBS2 | RNA-P7T1-P7T1-1 | Human | Lung | AIS | 4.73e-03 | 6.36e-01 | -0.0961 |
| 202559 | KHDRBS2 | RNA-P7T1-P7T1-2 | Human | Lung | AIS | 8.64e-05 | 7.56e-01 | -0.0876 |
| 202559 | KHDRBS2 | RNA-P7T1-P7T1-4 | Human | Lung | AIS | 2.20e-04 | 6.96e-01 | -0.0809 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004348413 | Lung | AIS | regulation of RNA splicing | 45/1849 | 148/18723 | 2.75e-12 | 2.67e-09 | 45 |
| GO:004802413 | Lung | AIS | regulation of mRNA splicing, via spliceosome | 32/1849 | 101/18723 | 1.20e-09 | 2.42e-07 | 32 |
| GO:190331112 | Lung | AIS | regulation of mRNA metabolic process | 60/1849 | 288/18723 | 1.74e-08 | 2.47e-06 | 60 |
| GO:005068412 | Lung | AIS | regulation of mRNA processing | 36/1849 | 137/18723 | 3.06e-08 | 3.79e-06 | 36 |
| GO:000038112 | Lung | AIS | regulation of alternative mRNA splicing, via spliceosome | 19/1849 | 60/18723 | 2.77e-06 | 1.52e-04 | 19 |
| GO:000038012 | Lung | AIS | alternative mRNA splicing, via spliceosome | 21/1849 | 77/18723 | 1.19e-05 | 4.71e-04 | 21 |
| GO:000838013 | Lung | AIS | RNA splicing | 68/1849 | 434/18723 | 8.50e-05 | 2.11e-03 | 68 |
| GO:000037713 | Lung | AIS | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 49/1849 | 320/18723 | 1.30e-03 | 1.63e-02 | 49 |
| GO:000039813 | Lung | AIS | mRNA splicing, via spliceosome | 49/1849 | 320/18723 | 1.30e-03 | 1.63e-02 | 49 |
| GO:000037513 | Lung | AIS | RNA splicing, via transesterification reactions | 49/1849 | 324/18723 | 1.69e-03 | 1.93e-02 | 49 |
| GO:004348433 | Lung | MIAC | regulation of RNA splicing | 32/967 | 148/18723 | 3.60e-12 | 9.23e-09 | 32 |
| GO:190331132 | Lung | MIAC | regulation of mRNA metabolic process | 45/967 | 288/18723 | 2.75e-11 | 4.70e-08 | 45 |
| GO:004802432 | Lung | MIAC | regulation of mRNA splicing, via spliceosome | 24/967 | 101/18723 | 2.28e-10 | 2.92e-07 | 24 |
| GO:005068432 | Lung | MIAC | regulation of mRNA processing | 26/967 | 137/18723 | 7.19e-09 | 4.94e-06 | 26 |
| GO:000038122 | Lung | MIAC | regulation of alternative mRNA splicing, via spliceosome | 14/967 | 60/18723 | 1.64e-06 | 2.10e-04 | 14 |
| GO:000838023 | Lung | MIAC | RNA splicing | 44/967 | 434/18723 | 1.56e-05 | 1.07e-03 | 44 |
| GO:000038022 | Lung | MIAC | alternative mRNA splicing, via spliceosome | 14/967 | 77/18723 | 3.50e-05 | 1.97e-03 | 14 |
| GO:000037723 | Lung | MIAC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 33/967 | 320/18723 | 1.27e-04 | 5.13e-03 | 33 |
| GO:000039823 | Lung | MIAC | mRNA splicing, via spliceosome | 33/967 | 320/18723 | 1.27e-04 | 5.13e-03 | 33 |
| GO:000037523 | Lung | MIAC | RNA splicing, via transesterification reactions | 33/967 | 324/18723 | 1.61e-04 | 6.19e-03 | 33 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| KHDRBS2 | SNV | Missense_Mutation | c.760N>A | p.Pro254Thr | p.P254T | Q5VWX1 | protein_coding | tolerated(0.32) | benign(0.003) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD | |
| KHDRBS2 | SNV | Missense_Mutation | c.604N>A | p.Pro202Thr | p.P202T | Q5VWX1 | protein_coding | tolerated(0.45) | benign(0.009) | TCGA-AR-A0TV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| KHDRBS2 | SNV | Missense_Mutation | novel | c.349N>T | p.Arg117Trp | p.R117W | Q5VWX1 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-VS-A9UY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| KHDRBS2 | SNV | Missense_Mutation | c.917N>T | p.Gly306Val | p.G306V | Q5VWX1 | protein_coding | deleterious(0) | possibly_damaging(0.548) | TCGA-AA-3713-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5-fluorouracil | PR | |
| KHDRBS2 | SNV | Missense_Mutation | novel | c.566N>A | p.Gly189Asp | p.G189D | Q5VWX1 | protein_coding | tolerated(0.13) | benign(0.156) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| KHDRBS2 | SNV | Missense_Mutation | rs201333575 | c.878N>T | p.Ala293Val | p.A293V | Q5VWX1 | protein_coding | tolerated(0.08) | benign(0.098) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| KHDRBS2 | SNV | Missense_Mutation | c.200N>T | p.Pro67Leu | p.P67L | Q5VWX1 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR | |
| KHDRBS2 | SNV | Missense_Mutation | c.199N>A | p.Pro67Thr | p.P67T | Q5VWX1 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR | |
| KHDRBS2 | SNV | Missense_Mutation | c.474N>A | p.Phe158Leu | p.F158L | Q5VWX1 | protein_coding | tolerated(0.06) | possibly_damaging(0.796) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
| KHDRBS2 | SNV | Missense_Mutation | c.964N>C | p.Trp322Arg | p.W322R | Q5VWX1 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |